Masked hypertension, that is normal clinic but high out-ofoffice blood pressure (BP), and white coat hypertension, that is high clinic but normal out-of-office BP, have been detected in untreated individuals, 1,2 treated patients, 3-8 and samples including both untreated and treated subjects. [9] [10] [11] [12] [13] [14] In treated hypertension, masked hypertension has later been renamed as masked uncontrolled hypertension (MUCH) 7, 8, 14 and white coat hypertension as white coat uncontrolled hypertension (WCUCH). 7 Interestingly, it has been reported that MUCH is associated with significantly higher risk, and WCUCH with not significantly higher risk, when compared to treated hypertensive patients with normal clinic and outof-office BP, that is controlled hypertension (CH). [3] [4] [5] 7, [9] [10] [11] [12] [13] MUCH and WCUCH can be detected by using either ambulatory BP monitoring 3, 5, [7] [8] [9] [10] [11] [12] or home BP recording. 4, 6, 13 However, it has been shown that home BP recording has not sufficient sensitivity or specificity to replace ambulatory BP monitoring as the reference standard for the diagnosis of hypertension 15 and that ambulatory BP monitoring has a better accuracy than home BP recording in the diagnosis of masked and white coat hypertension in untreated and treated subjects. 16 Moreover, it has been reported that ambulatory BP is more strongly associated with cardiovascular risk than home BP. 17 In the elderly, to the best of our knowledge, there are only 3 studies in the literature on the prognostic value of MUCH and WCUCH. 4, 10, 11 One study 4 evaluated these topics by using home BP recording, one 10 by using ambulatory BP monitoring and reporting data on untreated and treated patients analyzed together and one 11 by using ambulatory BP monitoring including only patients with isolated systolic hypertension. Thus, other data could be helpful to better understand the prognostic value of MUCH and WCUCH in this specific setting.
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The aim of this study was to evaluate the prognostic value of MUCH and WCUCH detected by ambulatory BP monitoring in elderly treated hypertensive patients.
METHODS

Subjects
Since 1992, we built 2 prospective databases of our initially untreated or initially treated hypertensive patients with the purpose to evaluate the prognostic value of ambulatory BP parameters and other risk markers. The present study is one of those carried out with the database of initially treated subjects. We studied 1,191 sequential treated hypertensive patients aged ≥60 years (range 60-90 years) prospectively recruited from December 1992 to 2012 and who were referred to our hospital outpatient clinic for evaluation of BP control. Sixty-two patients were lost during follow-up. Subjects with secondary hypertension were excluded. All the patients underwent clinical evaluation, electrocardiogram, routine laboratory tests, echocardiographic examination, and noninvasive ambulatory BP monitoring. Study population (native Caucasians) came from the same geographical area (Chieti and Pescara, Abruzzo, Italy). The study was in accordance with the Second Declaration of Helsinki and was approved by the institutional review committee. Subjects gave informed consent.
Office BP measurements
Clinic systolic and diastolic BP were recorded by a physician using a mercury sphygmomanometer (Welch Allyn Speidel & Keller, Germany) and appropriate-sized cuffs. Measurements were performed in triplicate, 2 minutes apart, and the mean value was used as the BP for the visit. Clinic BP was defined as normal when it was <140/90 mm Hg, according to the European Society of Hypertension and the European Society of Cardiology guidelines, regardless of comorbidities. 18 
Ambulatory BP monitoring
Ambulatory BP monitoring was performed with a portable noninvasive recorder (SpaceLabs 90207, Redmond, WA) on a day of typical activity, within 1 week from clinic BP measurement. Each time a reading was taken, subjects were instructed to remain motionless and to record their activity on a diary sheet. Ambulatory BP readings were obtained at 15-minute intervals from 6 am to midnight, and at 30-minute intervals from midnight to 6 am. The following ambulatory BP parameters were evaluated: daytime (awake period as reported in the diary), nighttime (asleep period as reported in the diary), and 24-hour systolic and diastolic BP. CH was defined as clinic BP <140/90 mm Hg and 24-hour BP <130/80 mm Hg, MUCH was defined as clinic BP <140/90 mm Hg and 24-hour BP ≥130 and/or ≥80 mm Hg, WCUCH was defined as clinic BP ≥140 and/ or ≥90 mm Hg and 24-hour BP <130/80 mm Hg and sustained uncontrolled hypertension (SUCH) was defined as clinic BP ≥140 and/or ≥90 mm Hg and 24-hour BP ≥130 and/or ≥80 mm Hg. 19 Recordings were automatically edited (that is, excluded) if systolic BP was >260 or <70 mm Hg or if diastolic BP was >150 or <40 mm Hg and pulse pressure was >150 or <20 mm Hg. Subjects had recordings of good technical quality (at least 70% of valid readings during the 24-hour period, at least 20 valid readings while awake with at least 2 valid readings per hour and at least 7 valid readings while asleep with at least 1 valid reading per hour), in line with minimum requirement suggested by the European Society of Hypertension. 19 
Echocardiography
Left atrial (LA) and left ventricular (LV) measurements and calculation of LV mass were made according to standardized methods. 20 LA diameter (cm) was indexed by body surface area (m 2 ) and LA enlargement was defined as LA diameter/body surface area ≥2.4 cm/m 2 . 20 LV mass was indexed by height 2.7 and LV hypertrophy was defined as LV mass/height 2.7 >50 g/m 2.7 in men and >47 g/m 2.7 in women. 21 LV ejection fraction was calculated using the Teichholz formula or the Simpson rule 20 and defined as low when it was <50%.
Follow-up
Subjects were followed-up in our hospital outpatient clinic or by their family doctors. The occurrence of cardiovascular events was recorded during follow-up visits or by telephone interview of the patient followed by a clinical visit. Data were collected by the authors of this study. Those reviewing the endpoints were blinded to other patients' data. In the present report, we evaluated a combined endpoint including fatal and nonfatal stroke, coronary events (sudden death, fatal and nonfatal myocardial infarction, and coronary revascularization), heart failure with reduced or preserved ejection fraction requiring hospitalization, and peripheral revascularization. Outcomes were defined as previously reported. [22] [23] [24] [25] We considered only the first event and recurrent events were excluded.
Statistical analysis
Standard descriptive statistics were used. Groups were compared by using 1-way analysis of variance followed by a multiple comparison test and chi-square or Fisher's exact test with Bonferroni's correction, where appropriate. Event rates are expressed as the number of events per 100 patientyears based on the ratio of the observed number of events to the total number of patient-years of exposure up to the terminating event or censor. Survival curves were estimated using the Kaplan-Meier product-limit method and compared by the Mantel (log-rank) test. Cox regression analysis was used to evaluate univariate and multivariate association of factors with outcome. First, we evaluated univariate association between cardiovascular events and age, gender, body mass index, smoking habit, previous events, diabetes, estimated glomerular filtration rate, low-density lipoprotein cholesterol, LV hypertrophy, asymptomatic LV systolic dysfunction at baseline, LA enlargement, clinic, daytime, nighttime and 24-hour systolic and diastolic BP, ambulatory BP group (CH as reference group and MUCH, WCUCH, and SUCH as comparing groups), antihypertensive, antiplatelet and statin therapy at baseline, and atrial fibrillation occurred during follow-up. Then, multiple regression analysis was performed reporting in the final model variables that were significantly (P < 0.05) associated with outcome in univariate analysis. The forced entry model was used. Statistical significance was defined as P < 0.05. Analyses were made with the SPSS 21 software package (SPSS, Chicago, IL). Graphs were made with GraphPad Prism 7 (GraphPad software, San Diego, CA).
RESULTS
One hundred and forty-two patients (12% of the global population and 34% of those with normal clinic BP) had MUCH and 230 patients (19% of the global population and 30% of those with high clinic BP) had WCUCH. Among patients (n = 506) with 24-hour BP <130/80 mm Hg, 391 had normal daytime and nighttime BP, 16 had high daytime and normal nighttime BP, and 99 had normal daytime and high nighttime BP. Among patients (n = 685) with 24-hour BP ≥130/80 mm Hg, 535 had high daytime and nighttime BP, 66 had high daytime and normal nighttime BP, and 84 had normal daytime and high nighttime BP.
Characteristics of study groups are reported in Table 1 . Patients with WCUCH and SUCH were older than those with CH and MUCH. Prevalence of men was higher in MUCH than in the other groups. Prevalence of smokers was higher in MUCH than in WCUCH and SUCH. Prevalence of diabetes was higher in SUCH than in CH. Estimated glomerular filtration rate was lower in WCUCH and SUCH than in MUCH. Low-density lipoprotein cholesterol was lower in WCUCH than in CH and SUCH. Prevalence of LV hypertrophy was higher in MUCH than in WCUCH and in SUCH than in CH and WCUCH. Prevalence of LA enlargement was higher in SUCH than in CH and WCUCH.
BP values are reported in Table 2 . Though in the normal range, clinic BP was higher in patients with MUCH than in those with CH; clinic BP was higher in patients with WCUCH and SUCH than in those with CH and MUCH by definition. Ambulatory BP was different across the groups by definition. Considering groups with normal 24-hour BP, daytime, and 24-hour systolic BP were higher in patients with WCUCH than in those with CH. Considering groups with high 24-hour BP, daytime, nighttime, and 24-hour systolic BP were higher in patients with SUCH than in those with MUCH.
Baseline antihypertensive therapy is reported in Table 3 . Use of diuretics was higher in patients with WCUCH and SUCH than in those with CH and MUCH. Use of angiotensin-converting enzyme inhibitors was higher in patients with WCUCH and SUCH than in those with MUCH. Single therapy was less frequent in WCUCH and SUCH than in CH and MUCH. Double therapy was more frequent in SUCH than in the other groups. Triple therapy was more frequent in WCUCH and SUCH than in CH and MUCH.
At baseline, use of aspirin (range 19-24%) and statin (range 9-16%) was not significantly different among the groups.
During the follow-up (9.1 ± 4.9 years, range 0.4-20 years), 392 cardiovascular events occurred. Specifically, there were 47 fatal and 92 nonfatal ischemic strokes, 5 fatal and 4 nonfatal hemorrhagic strokes, 35 fatal and 54 nonfatal myocardial infarctions, 31 coronary revascularizations, 123 heart failures (67 with preserved and 56 with reduced ejection fraction, 6 of which were preceded by a coronary event and 4 of which were preceded by a cerebrovascular event and excluded from the total count), and 11 peripheral revascularizations. The event-rate of the global population was 3.63 per 100 patientyears. In patients with CH, MUCH, WCUCH, and SUCH there were 60, 61, 47, and 224 events, respectively. Event-free survival curves of the study groups are reported in Figure 1 . Univariate analysis showed that age, diabetes, previous events, estimated glomerular filtration rate, LV hypertrophy, LA enlargement, asymptomatic LV systolic dysfunction at baseline, clinic, daytime, nighttime and 24-hour systolic BP, MUCH, and SUCH were significantly associated with increased cardiovascular risk (Table 4) . There was no significant association between cardiovascular risk and other variables.
We performed a multivariate analysis including age, diabetes, previous events, estimated glomerular filtration rate, LV hypertrophy, LA enlargement, asymptomatic LV systolic dysfunction at baseline and ambulatory BP groups. Results of multivariate analysis are reported in Figure 2 . After adjustment for the abovementioned covariates, the risk of cardiovascular events was significantly higher in patients with MUCH and SUCH than in those with CH, whereas it was not significantly different between WCUCH and CH.
DISCUSSION
This study shows that MUCH detected by ambulatory BP monitoring is associated with adverse prognosis in the elderly, whereas WCUCH is not.
Previous studies [3] [4] [5] 7, [9] [10] [11] [12] [13] have globally reported that MUCH, and not WCUCH, is associated with increased cardiovascular risk when compared to CH. However, there are only 3 studies in the literature evaluating these topics in the elderly. 4, 10, 11 Bobrie et al., 4 by using home BP recording, reported that elderly treated hypertensive patients (aged ≥60 years) with MUCH (clinic BP <140/90 mm Hg and home BP ≥135/85 mm Hg) were at higher cardiovascular risk than those with CH, whereas those with WCUCH were not. Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CH, controlled hypertension; MUCH, masked uncontrolled hypertension; SUCH, sustained uncontrolled hypertension; WCUCH, white coat uncontrolled hypertension. *P < 0.05 vs. CH; ‡ P < 0.05 vs. MUCH; † P < 0.05 vs. WCUCH. 11 Our study shows some differences with previous ones. 4,10,11 Indeed, we used ambulatory BP monitoring, reported data about only treated patients and included those who had systolic and diastolic hypertension. However, our results show the same trend as that observed in former studies. Thus, our data confirm and extend previous findings. This study has some limitations. First, we studied only Caucasian subjects and our results cannot be applied to other ethnic groups. Second, our data were obtained in elderly treated hypertensive patients and cannot be extrapolated to younger and untreated subjects. Third, the lack of association of cardiovascular risk with treatment strategy does not mean lack of efficacy of therapy because all subjects were treated with antihypertensive therapy, most of whom received multiple therapy, and patients were not randomized to antihypertensive or antiplatelet or statin therapy.
In conclusion, in elderly treated hypertensive patients evaluated by ambulatory BP monitoring, compared to individuals with CH, those with MUCH have significantly higher risk and those with WCUCH have slightly and not significantly higher risk. Our data suggest that elderly treated hypertensive patients with MUCH should receive optimized therapy for better BP control and further risk reduction and that those with WCUCH could remain with their treatment. 
